liver biopsy derived Hu-PHEC cells (HemoGenyx)

N/A

Report date: 2025/03/20 14:50:04

Base Information

Drug Nameliver biopsy derived Hu-PHEC cells (HemoGenyx)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionHaematopoiesis stimulants
TargetsUpdating
Therapy Area/IndicationsAnemia, AplasticHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHemogenyx Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesHemogenyx Pharmaceuticals PLC
Inactive CompaniesN/A
Active IndicationsAnemia, AplasticHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A